Treatment-Resistant Depression Management

Definition and Diagnosis

The American Psychiatric Association defines treatment-resistant depression (TRD) as failure of at least two adequate antidepressant trials with different mechanisms of action in the current depressive episode 1, 2, 3
Each trial must be at minimum effective dosage for at least 4 weeks duration 1, 4, 5, 3
Only treatment failures within the past 2 years should be considered for prolonged current episodes 3, 6
Discontinuation before 4 weeks due to side effects should not count as treatment failure unless there is clear evidence of non-response 4, 2, 5

The American College of Psychiatrists recommends augmentation with atypical antipsychotics, specifically aripiprazole, as the primary first-line strategy for treatment-resistant depression after failure of at least two adequate antidepressant trials with different mechanisms of action 3, 6, 7
Aripiprazole augmentation is recommended after inadequate response to at least one antidepressant at adequate dose for ≥4 weeks 3, 6, 7
Olanzapine-fluoxetine combination is FDA-approved for TRD, with a starting dose of 5 mg olanzapine with 20 mg fluoxetine once daily in the evening 7
Lithium augmentation is a well-studied alternative augmentation strategy with established efficacy 7
Transcranial magnetic stimulation (TMS) should be considered for patients who have failed medication trials 3, 6, 4, 8

Cognitive behavioral therapy should be used in conjunction with pharmacotherapy throughout treatment 3, 1, 2, 5
Psychotherapy failure does not count toward defining TRD but should be documented 1, 2, 5

Do not escalate antidepressant doses beyond minimum effective dosage, as most studies show no benefit with increased risk of side effects and discontinuation 4, 2, 5
Do not exclude patients based on number of prior medication failures, as multiple-drug resistant individuals should not be excluded from treatment trials 4, 8, 5, 3
Do not use inadequate trial duration, as stable response/remission typically requires 4 weeks minimum 4, 2, 5

The Maudsley Staging Method (MSM) is the preferred staging instrument for structured documentation, incorporating number of treatment failures, duration of illness, baseline symptom severity, augmentation strategies, and ECT history 3, 9, 10
The MSM correctly predicts treatment resistance in >85% of cases with prospective validation 3
The MSM produces a continuous score ranging from 3 to 15 9, 10

TRD is defined as the failure of at least two adequately dosed antidepressant trials, each employing a different mechanism of action, during the current depressive episode【11】.

Each trial must be administered at the minimum effective dose for a duration of at least 4 weeks【11】【12】.

Treatment failure is characterized by less than 25 % improvement in depressive symptoms despite appropriate dose and duration【11】.

For prolonged current episodes, only treatment failures occurring within the preceding 2 years should be counted toward the TRD definition【11】.

Verification of dose and duration must be obtained from objective clinical records (e.g., pharmacy, hospital, or electronic health records) rather than patient recollection【11】.